{"nctId":"NCT03036124","briefTitle":"Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure","startDateStruct":{"date":"2017-02-08","type":"ACTUAL"},"conditions":["Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)"],"count":4744,"armGroups":[{"label":"Dapagliflozin","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Dapagliflozin","otherNames":["Forxiga TM","Farxiga TM"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of signed informed consent prior to any study specific procedures\n* Male or female, aged ≥18 years\n* Established documented diagnosis of symptomatic HFrEF (NYHA functional class II-IV), which has been present for at least 2 months\n* LVEF≤40%\n* Elevated NT-proBNP levels\n* Patients should receive background standard of care for HFrEF and be treated according to locally recognized guidelines\n* eGFR ≥30 mL/min/1.73 m\\^2 (CKD-EPI formula) at enrolment (visit 1)\n\nExclusion Criteria:\n\n* Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor\n* Type 1 diabetes mellitus\n* Symptomatic hypotension or systolic BP \\<95 mmHg at 2 out of 3 measurements either at visit 1 or visit 2\n* Current acute decompensated HF or hospitalization due to decompensated HF \\<4 weeks prior to enrolment\n* MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment\n* Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization\n* Implantation of a CRT within 12 weeks prior to enrolment or intent to implant a CRT device\n* Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization\n* HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease\n* Symptomatic bradycardia or second or third degree heart block without a pacemaker\n* Severe (eGFR \\<30 mL/min/1.73 m\\^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.","description":"Primary efficacy","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"386","spread":null},{"groupId":"OG001","value":"502","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.","description":"Secondary","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"382","spread":null},{"groupId":"OG001","value":"495","spread":null}]}]}]},{"type":"SECONDARY","title":"Events Included in the Composite Endpoint of Recurrent Hospitalizations Due to Heart Failure and CV Death.","description":"Secondary","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"567","spread":null},{"groupId":"OG001","value":"742","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the KCCQ Total Symptom Score","description":"KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ total symptom score incorporates the symptom domains into a single score. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"18.6"},{"groupId":"OG001","value":"3.3","spread":"19.2"}]}]}]},{"type":"SECONDARY","title":"Subjects Included in the Composite Endpoint of ≥50% Sustained Decline in eGFR, ESRD or Renal Death.","description":"Secondary","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Included in the Endpoint of All-cause Mortality.","description":"Secondary","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"276","spread":null},{"groupId":"OG001","value":"329","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":895,"n":2368},"commonTop":["Cardiac failure","Hypotension","Nasopharyngitis","Renal impairment","Atrial fibrillation"]}}}